PolyPeptide
ActiveSummary
PolyPeptide has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €103.8m and a net result of €7.2m. Equity is growing by about 4% per year across the filed financial years. Its solvency ranks better than 29% of 91 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21100
2nd largest company by total assets in Walloon Brabant, Pharmaceuticals sector2 sites
Size
€156.1mturnover 2025
- Staff
- 485 FTE
- Equity
- €103.8m
- Profit
- €7.2m
Structure
- Parent
- Polypeptide Laboratories Holding (PPL) AB · 100%
- Polypeptide Laboratories Holding (PPL) ABDirector · permanent representative Jens FRICKE
Auditor: BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES2025 accounts 50 days early
Why 85raises riskLiquidity: current ratio 1.55, cash €87,135, halvedlowers riskSize: turnover €156.1m, 485 FTE, total assets €331.7mFounded in 2006Legal form: public limited companyShow the evidence
Checked score
Score 2025
85
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 42% of its sector peers (NACE 21)
Financial strength · tick = 2024
Average
Solvency
56-5
equity 31.3% of total assets
Liquidity
38-4
short-term debt 29.4% · cash 0.0%
Profitability
70+31
return on assets 2.2%
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.2%
12-2024: 0.2%● unchanged vs 11-2024
01-2025: 0.2%● unchanged vs 12-2024
02-2025: 0.2%● unchanged vs 01-2025lowest value
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.3%▲ +0.1 percentage points vs 06-2025
08-2025: 0.3%● unchanged vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.4%▲ +0.1 percentage points vs 05-2026highest value
07-2026: 0.3%▼ -0.1 percentage points vs 06-2026
08-2026: 0.3%● unchanged vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026
Credit of up to €8,800,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.55, compared with 1.68 in 2024, above the usual 1.5; short-term debt: 29.4% and cash: 0% of total assets), but 68.7% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21): better than 20% on solvency, 39% on liquidity, 51% on profitability and 60% on growth.
The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
50 days early
2024
58 days early
2023
64 days early
2022
62 days early
2021
52 days early
2020
65 days early
2019
57 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 58 days before the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 3 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
29-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · full…
- Back to profitnet €7.2m
- Equity above €100mequity €103.8m ▲7.4%
Financials · financial year 2025, full format
In the rankings
#2 company by total assets in Walloon Brabant, Pharmaceuticals sector#2 company by equity in Walloon Brabant, Pharmaceuticals sector#3 employer in Braine-l'Alleud, Manufacturing sector
Turnover
€156.1m▲ 22.0%
2024 · €127.9m
EBIT margin
10.2%▲ 6.2pp
2024 · 4.0%
Net result
€7.2m
2024 · -€3.2m
Working capital
€53.7m▲ 28.6%
2024 · €41.7m
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result recovers in 2025; 2025 is over 3.1 times 2024 and is the highest result in the available series.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Turnover€156.1m
2025
Operating result€15.9m
2025
Net result€7.2m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€331.7m
2025
Equity€103.8m
2025
Debt€226.3m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€53.7m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
EBIT margin10.2%
2025
Return on assets (ROA)2.2%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency31.3%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio1.55
2025
Average staff in full-time equivalents (FTE).
Staff (FTE)485
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€49.2m-€52.7m▲ 7.0%€53.8m▲ 2.1%€64.1m▲ 19.0%€98.7m▲ 54.0%€165.2m▲ 67.4%€127.9m▼ 22.6%€156.1m▲ 22.0%
Operating result€5.5m-€5.5m▲ 0.6%€5.1m▼ 7.5%€5.9m▲ 14.4%€7.0m▲ 19.0%€6.3m▼ 10.1%€5.1m▼ 18.8%€15.9m▲ 213%
Net result€5.1m-€4.8m▼ 6.3%€4.5mabove the sector's middle half▼ 4.5%€4.9mabove the sector's middle half▲ 7.8%€5.4mabove the sector's middle half▲ 11.1%€1.7mwithin the sector's middle half▼ 68.2%-€3.2mbelow the sector's middle half€7.2mabove the sector's middle half
EBIT margin11.2%-10.5%▼ 0.7pp9.5%▼ 1.0pp9.1%▼ 0.4pp7.1%▼ 2.1pp3.8%▼ 3.3pp4.0%▲ 0.2pp10.2%▲ 6.2pp
Equity€78.7m-€83.4m▲ 6.0%€87.9mabove the sector's middle half▲ 5.4%€92.7mabove the sector's middle half▲ 5.5%€98.1mabove the sector's middle half▲ 5.8%€99.8mabove the sector's middle half▲ 1.7%€96.6mabove the sector's middle half▼ 3.2%€103.8mabove the sector's middle half▲ 7.4%
Total assets€99.7m-€108.9m▲ 9.3%€110.3mabove the sector's middle half▲ 1.3%€145.8mabove the sector's middle half▲ 32.2%€209.6mabove the sector's middle half▲ 43.8%€254.3mabove the sector's middle half▲ 21.3%€271.1mabove the sector's middle half▲ 6.6%€331.7mabove the sector's middle half▲ 22.4%
Debt€20.0m-€24.7m▲ 23.7%€21.9m▼ 11.4%€52.6m▲ 140%€110.4m▲ 110%€154.0m▲ 39.5%€173.5m▲ 12.7%€226.3m▲ 30.4%
Working capital€32.0m-€43.3m▲ 35.3%€36.2mabove the sector's middle half▼ 16.2%€48.7mabove the sector's middle half▲ 34.2%€61.5mabove the sector's middle half▲ 26.4%€50.9mabove the sector's middle half▼ 17.3%€41.7mabove the sector's middle half▼ 18.0%€53.7mabove the sector's middle half▲ 28.6%
Solvency79.0%-76.6%▼ 2.4pp79.7%above the sector's middle half▲ 3.1pp63.6%above the sector's middle half▼ 16.1pp46.8%within the sector's middle half▼ 16.8pp39.3%within the sector's middle half▼ 7.6pp35.6%within the sector's middle half▼ 3.6pp31.3%within the sector's middle half▼ 4.4pp
Current ratio2.63-4.17▲ 1.543.45above the sector's middle half▼ 0.723.19above the sector's middle half▼ 0.272.48within the sector's middle half▼ 0.711.74within the sector's middle half▼ 0.731.68within the sector's middle half▼ 0.061.55within the sector's middle half▼ 0.13
Return on assets (ROA)5.1%-4.4%▼ 0.7pp4.1%within the sector's middle half▼ 0.2pp3.4%within the sector's middle half▼ 0.8pp2.6%within the sector's middle half▼ 0.8pp0.7%within the sector's middle half▼ 1.9pp-1.2%within the sector's middle half▼ 1.8pp2.2%within the sector's middle half▲ 3.4pp
Staff (FTE)237.7-240.1▲ 1.0%265.7above the sector's middle half▲ 10.7%317.2above the sector's middle half▲ 19.4%394above the sector's middle half▲ 24.2%437.8above the sector's middle half▲ 11.1%468.1above the sector's middle half▲ 6.9%485above the sector's middle half▲ 3.6%
above
within
below
the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €331.7m
Fixed assets
€180.6m ▲ 7.3%
Current assets
€151.2m ▲ 47.1%
Equity and liabilities €331.7m
Equity
€103.8m ▲ 7.4%
Provisions
€1.6m ▲ 71.8%
Debt
€226.3m ▲ 30.4%
Debt's share of the balance-sheet total rises from 64.0% to 68.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€27.1m▲
2024 · €11.1m
Cash flow
€18.4m▲
2024 · €2.9m
Quick ratio
0.65▲
2024 · 0.53
Debt to equity
2.18▲
2024 · 1.80
ROE
7.0%▲
2024 · -3.3%
Interest coverage
4.63▲
2024 · 1.65
Debt ≤ 1 year
€97.5m▲
2024 · €61.1m
Debt > 1 year
€128.7m▲
2024 · €112.2m
Income taxes
€2.8m▲
2024 · €435,169
Staff costs
€56.8m▲
2024 · €51.1m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 513 companies that looked in July 2024 the way this one looks now, 0.8% went bankrupt within 24 months and 96.1% are still going.
- Large
- 20 years or older
- solvency 30% or more
- a profit under 5% of the balance sheet
0.8%
went bankrupt
3.1%
stopped otherwise
96.1%
still going
For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 513 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | - | €83.1m | €108.6m | €153.1m | €137.8m | €166.3m | ▲ 20.7% |
| Turnover70 | €49.2m | €52.7m | €53.8m | €64.1m | €98.7m | €165.2m | €127.9m | €156.1m | ▲ 22.0% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | - | - | - | €15.1m | €5.8m | -€17.3m | €2.1m | €4.1m | ▲ 98.2% |
| Own construction capitalised72 | - | - | - | €1.0m | €0.6m | €1.2m | €2.8m | €0.8m | ▼ 70.0% |
| Other operating income74 | - | - | - | €2.8m | €3.5m | €4.1m | €5.0m | €5.3m | ▲ 5.9% |
| Non-recurring operating income76A | - | - | - | €0.04m | €0.08m | - | - | - | - |
| Operating charges60/66A | - | - | - | €77.2m | €101.7m | €146.9m | €132.7m | €150.4m | ▲ 13.4% |
| Goods for resale, raw materials and consumables60 | - | - | - | €17.2m | €24.1m | €44.7m | €28.5m | €47.0m | ▲ 65.2% |
| Purchases600/8 | - | - | - | €24.6m | €36.3m | - | €32.5m | €57.4m | ▲ 76.7% |
| Change in stocks: decrease (increase)609 | - | - | - | -€7.4m | -€12.2m | -€6.5m | -€4.0m | -€10.4m | ▼ 158% |
| Services and other goods61 | - | - | - | €21.7m | €30.1m | €39.3m | €46.5m | €37.5m | ▼ 19.2% |
| Remuneration, social security and pensions62 | - | - | - | €29.8m | €39.5m | €46.9m | €51.1m | €56.8m | ▲ 11.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €4.4m | €4.7m | €5.1m | €5.5m | €6.3m | €8.1m | €6.0m | €11.2m | ▲ 85.6% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €2.9m | €0.7m | €5.6m | -€1.8m | -€3.1m | ▼ 74.1% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | -€0.05m | €0.6m | -€0.7m | €0.5m | €0.7m | ▲ 32.8% |
| Other operating charges640/8 | - | - | - | €0.2m | €0.4m | €0.2m | €0.4m | €0.3m | ▼ 21.4% |
| Non-recurring operating charges66A | - | - | - | €216 | €0.07m | €2.6m | €1.4m | €0.01m | ▼ 99.2% |
| Operating profit (loss)9901 | €5.5m | €5.5m | €5.1m | €5.9m | €7.0m | €6.3m | €5.1m | €15.9m | ▲ 213% |
| Financial income75/76B | - | - | - | €0.5m | €2.3m | - | €0.7m | €1.6m | ▲ 140% |
| Recurring financial income75 | €0.3m | €0.09m | €0.2m | €0.5m | €2.3m | €1.8m | €0.7m | €1.6m | ▲ 140% |
| Other financial income752/9 | - | - | - | €0.5m | €2.3m | €1.8m | €0.7m | €1.6m | ▲ 140% |
| Financial charges65/66B | - | - | - | €1.0m | €3.2m | €5.9m | €8.5m | €7.5m | ▼ 11.9% |
| Recurring financial charges65 | €0.5m | €0.3m | €0.4m | €1.0m | €3.2m | €5.9m | €8.5m | €7.5m | ▼ 11.9% |
| Debt charges650 | €0.2m | €0.2m | €0.1m | €0.2m | €1.2m | €4.4m | €6.7m | €5.8m | ▼ 13.2% |
| Other financial charges652/9 | - | - | - | €0.8m | €2.0m | €1.5m | €1.8m | €1.6m | ▼ 7.0% |
| Profit (loss) for the period before taxes9903 | €5.4m | €5.4m | €4.9m | €5.3m | €6.0m | €2.1m | -€2.7m | €10.1m | - |
| Income taxes67/77 | €0.3m | €0.6m | €0.4m | €0.4m | €0.5m | €0.4m | €0.4m | €2.8m | ▲ 548% |
| Taxes670/3 | - | - | - | €0.4m | €0.5m | €0.4m | €0.4m | €2.8m | ▲ 548% |
| Profit (loss) for the period9904 | €5.1m | €4.8m | €4.5m | €4.9m | €5.4m | €1.7m | -€3.2m | €7.2m | - |
| Profit (loss) for the period to be appropriated9905 | €5.1m | €4.8m | €4.5m | €4.9m | €5.4m | €1.7m | -€3.2m | €7.2m | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €99.7m | €108.9m | €110.3m | €145.8m | €209.6m | €254.3m | €271.1m | €331.7m | ▲ 22.4% |
| Fixed assets21/28 | €48.1m | €52.0m | €59.3m | €74.9m | €106.6m | €135.1m | €168.3m | €180.6m | ▲ 7.3% |
| Intangible fixed assets21 | €5.7m | €5.1m | €4.3m | €3.5m | €2.7m | €0.2m | €0.2m | €0.2m | ▼ 13.3% |
| Tangible fixed assets22/27 | €42.4m | €46.9m | €55.0m | €71.4m | €103.9m | €134.9m | €168.1m | €180.4m | ▲ 7.3% |
| Land and buildings22 | - | - | - | €11.4m | €12.9m | €14.8m | €25.9m | €27.4m | ▲ 5.9% |
| Plant, machinery and equipment23 | - | - | - | €27.6m | €39.1m | €38.2m | €91.4m | €116.1m | ▲ 27.0% |
| Furniture and vehicles24 | - | - | - | €2.1m | €1.8m | €1.8m | €6.9m | €16.1m | ▲ 135% |
| Leasing and similar rights25 | - | - | - | €1.2m | €1.8m | €4.3m | €3.8m | €3.5m | ▼ 6.7% |
| Assets under construction and advance payments27 | - | - | - | €29.1m | €48.2m | €75.8m | €40.2m | €17.3m | ▼ 57.0% |
| Financial fixed assets28 | €0.005m | €0.005m | €0.005m | €0.005m | - | - | - | - | - |
| Other financial fixed assets284/8 | - | - | - | €0.005m | - | - | - | - | - |
| Amounts receivable and cash guarantees285/8 | - | - | - | €0.005m | - | - | - | - | - |
| Current assets29/58 | €51.6m | €56.9m | €51.0m | €70.9m | €103.1m | €119.2m | €102.8m | €151.2m | ▲ 47.1% |
| Stocks and contracts in progress3 | €34.5m | €32.3m | €42.1m | €61.7m | €79.1m | €62.6m | €70.5m | €88.1m | ▲ 24.9% |
| Stocks30/36 | - | - | - | €61.7m | €79.1m | €62.6m | €70.5m | €88.1m | ▲ 24.9% |
| Raw materials and consumables30/31 | - | - | - | €24.7m | €36.0m | €41.6m | €45.2m | €43.5m | ▼ 3.7% |
| Work in progress32 | - | - | - | €29.5m | €27.1m | €14.5m | €21.4m | €44.1m | ▲ 106% |
| Finished goods33 | - | - | - | €7.5m | €16.0m | €6.5m | €3.9m | €0.4m | ▼ 88.9% |
| Amounts receivable within one year40/41 | €16.1m | €22.2m | €7.7m | €4.7m | €21.7m | €52.8m | €31.8m | €62.9m | ▲ 97.8% |
| Trade receivables40 | - | - | - | €4.1m | €21.6m | €52.6m | €31.3m | €62.3m | ▲ 99.3% |
| Other amounts receivable41 | - | - | - | €0.6m | €0.05m | €0.2m | €0.5m | €0.6m | ▲ 10.4% |
| Cash at bank and in hand54/58 | €0.8m | €2.4m | €1.2m | €4.3m | €2.1m | €3.4m | €0.3m | €0.09m | ▼ 71.6% |
| Deferred charges and accrued income490/1 | - | - | - | €0.2m | €0.3m | €0.3m | €0.2m | €0.1m | ▼ 42.7% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €99.7m | €108.9m | €110.3m | €145.8m | €209.6m | €254.3m | €271.1m | €331.7m | ▲ 22.4% |
| Equity10/15 | €78.7m | €83.4m | €87.9m | €92.7m | €98.1m | €99.8m | €96.6m | €103.8m | ▲ 7.4% |
| Contributions10/11 | €40.0m | €40.0m | €40.0m | €40.0m | €40.0m | €40.0m | €40.0m | €40.0m | = |
| Capital10 | - | - | - | €40.0m | €40.0m | €40.0m | €40.0m | €40.0m | = |
| Issued capital100 | - | - | - | €40.0m | €40.0m | €40.0m | €40.0m | €40.0m | = |
| Reserves13 | €1.9m | €2.1m | €2.4m | €2.6m | €2.9m | €3.0m | €3.0m | €3.3m | ▲ 12.2% |
| Non-distributable reserves130/1 | - | - | - | €2.6m | €2.9m | €3.0m | €3.0m | €3.3m | ▲ 12.2% |
| Legal reserve130 | - | - | - | €2.6m | €2.9m | €3.0m | €3.0m | €3.3m | ▲ 12.2% |
| Profit (loss) carried forward14 | €36.2m | €40.8m | €45.1m | €49.7m | €54.9m | €56.6m | €53.4m | €60.3m | ▲ 12.9% |
| Investment grants15 | - | - | - | €0.4m | €0.3m | €0.3m | €0.2m | €0.2m | ▼ 21.1% |
| Provisions and deferred taxes16 | €1.0m | €0.8m | €0.5m | €0.5m | €1.1m | €0.4m | €0.9m | €1.6m | ▲ 71.8% |
| Provisions for liabilities and charges160/5 | - | - | - | €0.5m | €1.1m | €0.4m | €0.9m | €1.6m | ▲ 71.8% |
| Pensions and similar obligations160 | - | - | - | €0.4m | €1.0m | €0.4m | €0.9m | €0.8m | ▼ 5.9% |
| Other liabilities and charges164/5 | - | - | - | €0.09m | €0.07m | €0.03m | €0.07m | €0.8m | ▲ 11× |
| Amounts payable17/49 | €20.0m | €24.7m | €21.9m | €52.6m | €110.4m | €154.0m | €173.5m | €226.3m | ▲ 30.4% |
| Amounts payable after more than one year17 | - | €10.9m | €6.9m | €28.2m | €68.3m | €85.6m | €112.2m | €128.7m | ▲ 14.6% |
| Financial debts170/4 | - | - | - | €28.2m | €68.3m | €85.6m | €112.2m | €128.7m | ▲ 14.6% |
| Leasing and similar obligations172 | - | - | - | €0.7m | €1.1m | €2.8m | €2.1m | €1.5m | ▼ 27.6% |
| Other loans174 | - | - | - | €27.5m | €67.2m | €82.7m | €110.1m | €127.1m | ▲ 15.4% |
| Amounts payable within one year42/48 | €19.6m | €13.6m | €14.8m | €22.3m | €41.6m | €68.3m | €61.1m | €97.5m | ▲ 59.7% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.2m | €0.4m | €0.9m | €0.9m | €0.6m | ▼ 31.9% |
| Trade debts44 | €4.4m | €8.5m | €10.4m | €16.9m | €35.5m | €56.3m | €50.9m | €74.2m | ▲ 45.8% |
| Suppliers440/4 | - | - | - | €16.9m | €35.5m | €56.3m | €50.9m | €74.2m | ▲ 45.8% |
| Taxes, remuneration and social security45 | - | - | - | €3.6m | €5.6m | €11.2m | €9.3m | €15.7m | ▲ 68.9% |
| Taxes450/3 | - | - | - | €0.005m | €0.9m | €5.0m | €3.6m | €7.3m | ▲ 106% |
| Remuneration and social security454/9 | - | - | - | €3.6m | €4.7m | €6.1m | €5.7m | €8.3m | ▲ 45.7% |
| Other amounts payable47/48 | - | - | - | €1.5m | €0.04m | €0.008m | €0.008m | €7.0m | ▲ 852× |
| Accrued charges and deferred income492/3 | - | - | - | €2.1m | €0.5m | €0.1m | €0.2m | €0.2m | ▼ 28.1% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €5.1m | €4.8m | €4.5m | €4.9m | €5.4m | €1.7m | -€3.2m | €7.2m | - |
| + Depreciation and write-downs630 | €4.4m | €4.7m | €5.1m | €5.5m | €6.3m | €8.1m | €6.0m | €11.2m | ▲ 85.6% |
| Operating cash flow (approximation) | €9.5m | €9.5m | €9.7m | €10.4m | €11.7m | €9.9m | €2.9m | €18.4m | ▲ 545% |
| Investment in fixed assets (approximation) | - | -€8.6m | -€12.4m | -€21.0m | -€38.0m | -€36.7m | -€39.2m | -€23.5m | ▲ 40.2% |
| Change in cash | - | €1.6m | -€1.2m | €3.1m | -€2.2m | €1.4m | -€3.1m | -€0.2m | ▲ 93.0% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 20 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | full format | 11-06-2026 | 2026-00165111 |
| 31-12-2024 | full format | 03-06-2025 | 2025-00124119 |
| 31-12-2023 | full format | 28-05-2024 | 2024-00100521 |
| 31-12-2022 | full format | 30-05-2023 | 2023-00110337 |
| 31-12-2021 | full format | 09-06-2022 | 2022-20059559 |
| 31-12-2020 | full format | 27-05-2021 | 2021-15400468 |
| 31-12-2019 | full format | 04-06-2020 | 2020-15000577 |
| 31-12-2018 | full format | 18-07-2019 | 2019-34900138 |
| 31-12-2017 | full format | 25-06-2018 | 2018-22100101 |
| 31-12-2016 | full format | 13-07-2017 | 2017-32000488 |
Similar companies · same sector, comparable size
TELIX INNOVATIONS
BE 0627.636.718
Herstal · equity €116.7m
JNTL Consumer Health (Belgium)
BE 0782.678.251
Antwerpen · equity €133.4m
Catalent Gosselies
BE 0840.843.708
Charleroi · equity €53.7m
MECS EUROPE/AFRICA
BE 0875.005.128
Hoeilaart · equity €36.5m
AJINOMOTO OMNICHEM
BE 0403.078.352
Wetteren · equity €323.9m
Of the 148 active companies whose main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100), figures are known for 109. 12 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
1 director, no change since 2023
Board 1
Polypeptide Laboratories Holding (PPL) AB
CurrentSole director · since 17-05-2023 · Legal entity · permanent representative: Jens FRICKE
8 not recently confirmed
Still in office according to the deeds, but no deed of the last six years confirms the mandate. Mandates like this have often ended since, in a deed we have not read yet.
Stefan Stoffel
Not recently confirmedDirector · since 18-05-2010
Toralf Haag
Not recently confirmedDirector · since 17-05-2011
Abraham Arjen Vermeer
Not recently confirmedDirector · since 16-01-2012
Peter Nilsson
Not recently confirmedDirector · since 03-01-2017
El-Djouhar Alexandra Rekai
Not recently confirmedDirector
Geneviève De Bue
Not recently confirmedDirector
Mireille Colette B. Leclercq
Not recently confirmedDirector
Serge Marie J Doris
Not recently confirmedDirector
Day-to-day management 5
Alain Scarso
Not recently confirmedDaily management delegate · since 10-02-2006
Stéphane Mischler
Not recently confirmedDaily management delegate · since 10-02-2006
Bert Irma V Variroye
Not recently confirmedDirecteur général adjoint · since 30-04-2013
Frédérique Marie Vogeleiser ep. Mutterer
Not recently confirmedDirecteur général · since 30-04-2013
Frédérique Vogeleisen
Not recently confirmedDélégué à la gestion journalière / directeur général · since 01-05-2013
Permanent representatives 1
Jens FRICKE
CurrentPermanent representative · since 17-05-2023 · for Polypeptide Laboratories Holding (PPL) AB
Statutory auditor 1
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
CurrentStatutory auditor · since 15-05-2018 · permanent representative: Rodrigo ABELS
Other functions 5
Patrick Loosen
Not recently confirmedMandataire spécial · since 19-05-2011
Eugénia Tsirimikos
Not recently confirmedMandataire · since 26-03-2014
M. Serge Doris
Not recently confirmedMandataire · since 26-03-2014
Mireille Leclercq
Not recently confirmedMandataire · since 26-03-2014
Mme Gerieviève De Bue
Not recently confirmedMandataire · since 26-03-2014
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Mandate history
47 people since 2006, 20 in office
- Board
- Day-to-day management
- Statutory auditor
- Other function
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| Polypeptide Laboratories Holding (PPL) AB |
|
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES |
|
| Stefan Stoffel |
|
| Toralf Haag |
|
| Abraham Arjen Vermeer |
|
| El-Djouhar Alexandra Rekai |
|
| Geneviève De Bue |
|
| Mireille Colette B. Leclercq |
|
| Serge Marie J Doris |
|
| Peter Nilsson |
|
| Alain Scarso |
|
| Stéphane Mischler |
|
| Bert Irma V Variroye |
|
| Frédérique Marie Vogeleiser ep. Mutterer |
|
| Frédérique Vogeleisen |
|
| Patrick Loosen |
|
| Eugénia Tsirimikos |
|
| M. Serge Doris |
|
| Mireille Leclercq |
|
| Mme Gerieviève De Bue |
|
| Jan Fuhr MILLER |
|
| Jens FRICKE |
|
| Vincenzo MANCUSO |
|
| Raymond DE VRÉ |
|
| Daniel LASANOW |
|
| Jane Salik |
|
| Lars-Göran Peter Nilsson |
|
| KPMG Réviseurs d'Entreprises SC SCRL |
|
| Alain Marlier |
|
| Christian Cromlin |
|
| Klynveld Peat Marwick Goerdeler - KPMG SCRL |
|
| Bert Vanroye |
|
| Frédérique Marie Vogeleisen |
|
| Daniel Blättler |
|
| Rodolfo Jose Savitzky |
|
| Stefan Heinz Stoffel |
|
| Toralf Andrew Haag |
|
| Klynveld Peat Marwick Goedeler - KPMG SCRL |
|
| Stephan Kutzer |
|
| Arjen Vermeer |
|
| James Leresche |
|
| Laurent Demoisy |
|
| Olivier Ludemann-Hombourger |
|
| Pascal Brouyère |
|
| Uwe Boehlke |
|
| Seppe De Gelas |
|
| Lukas Utiger |
|
Owners and capital
Owners
2 ownersChain of control
- Polypeptide Group AGCH
- Polypeptide Laboratories Holding (PPL) ABSE
- PolyPeptide
Highest known parent: Polypeptide Group AG (Switzerland). The sources do not say who stands above it.
Owners 2
- Polypeptide Laboratories Holding (PPL) ABSEparentSourceown accounts 2025100%
- Polypeptide Group AGCHconsolidating parentconsolidates
According to the 2025 annual accounts of PolyPeptide and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
Shareholders according to the deeds
After the capital increase
act of 29-08-2007 ↗
- Lonza AG
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 29-12-2021 Capital stated in the deed · €40,000,000 · 40,000 shares
- 24-01-2013 Capital increase of €63,800,000 · to €103,800,000 · in kind
- 24-01-2013 Capital reduction of €63,800,000 · to €40,000,000 · to absorb losses
- 29-08-2007 Capital increase of €20,000,000 · to €40,000,000 · 20,000 new shares · in kind
Group and network
Connections & network
2 connected companiesThe connected companies are in the list below.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
HAINAUT - NAMUR FORMATION
Shared director
→
Société Européenne de Galvanisation
Shared director
→
History
On 14 February 2006, PolyPeptide was incorporated.1 The capital was increased 2 times between 2007 and 2013, most recently to €103.8m.23 The name was changed to PolyPeptide in 2017.4 Polypeptide Laboratories Holding (PPL) AB has served as sole director of the company since 2023.5 Turnover went from €49.2m in 2018 to €156.1m in 2025 and headcount from 238 to 485 full-time equivalents.6
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
11-06
NBB filing
Annual accounts filed
financial year 2025 · full format
2025
31-12
Financial
Back to profitnet €7.2m
Net result €7.2m after one loss-making year.
31-12
Financial
Equity above €100mequity €103.8m ▲7.4%
Equity rises from €96.6m to €103.8m.
18-11
Gazette deed
Permanent representatives: Raoul BERNHARDT and Jens FRICKE4 facts ▸
Gazette deed
Permanent representatives: Raoul BERNHARDT and Jens FRICKE
4 facts ▸
- General meeting, 30-09-2025
- Permanent representative, Raoul BERNHARDT
- Permanent representative, Jens FRICKE
- Director in office, Polypeptide Laboratories Holding (PPL) AB (sole director)
03-06
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
31-12
Financial
Weakest financial yearnet -€3.2m
Net result drops to -€3.2m, the lowest in the series; recovery starts the following year.
18-06
Gazette deed
Reappointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)Permanent representative: Rodrigo ABELS3 facts ▸
Gazette deed
Reappointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)
Permanent representative: Rodrigo ABELS3 facts ▸
- General meeting, 21-05-2024
- Auditor reappointment, BDO Réviseurs d'Entreprises SRL (statutory auditor)
- Permanent representative, Rodrigo ABELS (représentant permanent chargé de l'exercice de son mandat)
28-05
NBB filing
Annual accounts filed
financial year 2023 · full format
02-04
Gazette deed
Resignations & appointmentsPower of attorney2 facts ▸
Gazette deed
Resignations & appointments
Power of attorney2 facts ▸
- Board meeting, 14-03-2024
- Power of attorney, El Djouhar Rekai
2023
13-06
Gazette deed
Resignations: Vincenzo MANCUSO, Jens FRICKE and Jan Fuhr MILLERAppointment: PolyPeptide Laboratories Holding (PPL) AB (sole director) · Permanent representative: Jens FRICKE · Power of attorney9 facts ▸
Gazette deed
Resignations: Vincenzo MANCUSO, Jens FRICKE and Jan Fuhr MILLER
Appointment: PolyPeptide Laboratories Holding (PPL) AB (sole director) · Permanent representative: Jens FRICKE · Power of attorney9 facts ▸
- General meeting, 16-05-2023
- Director resignation, Vincenzo MANCUSO (director)
- Director resignation, Jens FRICKE (director)
- Director resignation, Jan Fuhr MILLER (director)
- Director appointment, PolyPeptide Laboratories Holding (PPL) AB (sole director)
- Permanent representative, Jens FRICKE
- Other provision, “administrateur unique, mode d'administration” (deed in French)
- Board meeting, 23-05-2023
- Power of attorney, Ei Djouhar Rekal
30-05
NBB filing
Annual accounts filed
financial year 2022 · full format
23-03
Gazette deed
Resignation: Raymond DE VRÉ (director)Appointment: Jens FRICKE (director) · Power of attorney8 facts ▸
Gazette deed
Resignation: Raymond DE VRÉ (director)
Appointment: Jens FRICKE (director) · Power of attorney8 facts ▸
- General meeting, 02-03-2023
- Director resignation, Raymond DE VRÉ (director)
- Director appointment, Jens FRICKE (director)
- Board composition, MILLER Jan (director)
- Board composition, Jens FRICKE (director)
- Board composition, Vincenzo Mancuso (director)
- Board meeting, 02-03-2023
- Power of attorney, Vincenzo Mancuso
Show earlier events
2022
28-12
Gazette deed
Resignation: Daniel LASANOW (director)Appointment: Jan Fuhr MILLER (director) · Director discharge7 facts ▸
Gazette deed
Resignation: Daniel LASANOW (director)
Appointment: Jan Fuhr MILLER (director) · Director discharge7 facts ▸
- General meeting, 08-12-2022
- Director resignation, Daniel LASANOW (director)
- Director discharge, Daniel LASANOW (director)
- Director appointment, Jan Fuhr MILLER (director)
- Board composition, Jan Fuhr MILLER (director)
- Board composition, DE VRÉ Raymond (director)
- Board composition, MANCUZO Vincenzo (director)
14-06
Gazette deed
Reappointment: Daniel LASANOW (director)Mandate compensation3 facts ▸
Gazette deed
Reappointment: Daniel LASANOW (director)
Mandate compensation3 facts ▸
- General meeting, 17-05-2022
- Director reappointment, Daniel LASANOW (director)
- Mandate compensation, Daniel LASANOW
09-06
NBB filing
Annual accounts filed
financial year 2021 · full format
2021
29-12
Gazette deed
Amendment of the articlesCapital3 facts ▸
Gazette deed
Amendment of the articles
Capital3 facts ▸
- General meeting, 16-12-2021
- Amendment of the articles
- Capital, €40,000,000
20-12
Gazette deed
Resignations: Jane Salik, Jan Fuhr Miller and 2 othersAppointments: Raymond De Vré (director) and Vincenzo Mancuso (director) · Mandate compensation · Power of attorney16 facts ▸
Gazette deed
Resignations: Jane Salik, Jan Fuhr Miller and 2 others
Appointments: Raymond De Vré (director) and Vincenzo Mancuso (director) · Mandate compensation · Power of attorney16 facts ▸
- General meeting, 30-11-2021
- Board meeting, 30-11-2021
- Director resignation, Jane Salik (director)
- Director resignation, Jan Fuhr Miller (director)
- Director resignation, Lars-Göran Peter (Peter) Nilsson (director)
- Director appointment, Raymond De Vré (director)
- Director appointment, Vincenzo Mancuso (director)
- Mandate compensation, Raymond De Vré
- Mandate compensation, Vincenzo Mancuso
- Power of attorney, Deloitte Legal - Lawyers
- Power of attorney, Hanna Soininen
- Power of attorney, Benoit Massez
- +4 further facts in this act
31-08
Gazette deed
Appointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)Power of attorney3 facts ▸
Gazette deed
Appointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)
Power of attorney3 facts ▸
- General meeting, 18-05-2021
- Auditor appointment, BDO Réviseurs d'Entreprises SRL (statutory auditor)
- Power of attorney, Gauthier DAVIGNON
27-05
NBB filing
Annual accounts filed
financial year 2020 · full format
2020
04-06
NBB filing
Annual accounts filed
financial year 2019 · full format
26-03
Gazette deed
Resignations & appointmentsPower of attorney3 facts ▸
Gazette deed
Resignations & appointments
Power of attorney3 facts ▸
- Board meeting, 06-02-2020
- Power of attorney, Serge Doris
- Power of attorney, Hanna Soininen (2 times)
03-02
Gazette deed
Permanent representative: Rodrigo Abels1 fact ▸
Gazette deed
Permanent representative: Rodrigo Abels
1 fact ▸
- Permanent representative, Rodrigo Abels (représentant du commissaire)
2019
18-07
NBB filing
Annual accounts filed
financial year 2018 · full format
26-06
Gazette deed
Appointments: Vincenzo Mancuso (personne chargée de la gestion journalière et directeur général) and El Djouhar Alexandra Rekai (personne chargée de la gestion journalière et directeur général adjoint)3 facts ▸
Gazette deed
Appointments: Vincenzo Mancuso (personne chargée de la gestion journalière et directeur général) and El Djouhar Alexandra Rekai (personne chargée de la gestion journalière et directeur général adjoint)
3 facts ▸
- Board meeting, 16-04-2019
- Director appointment, Vincenzo Mancuso (personne chargée de la gestion journalière et directeur général)
- Director appointment, El Djouhar Alexandra Rekai (personne chargée de la gestion journalière et directeur général adjoint)
2018
25-09
Gazette deed
Resignations: Christian Cromlin (personne chargée de la gestion journalière et directeur général) and Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)Power of attorney8 facts ▸
Gazette deed
Resignations: Christian Cromlin (personne chargée de la gestion journalière et directeur général) and Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)
Power of attorney8 facts ▸
- Board meeting, 27-06-2018
- Director resignation, Christian Cromlin (personne chargée de la gestion journalière et directeur général)
- Director resignation, Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)
- Power of attorney, El Djouhar Alexandra Rekai (3 times)
- Power of attorney, Geneviève De Bue (3 times)
- Power of attorney, Serge Doris (3 times)
- Power of attorney, Olivier Gaziaux (3 times)
- Power of attorney, Benoit Massez (2 times)
26-07
Gazette deed
Appointments: KPMG Réviseurs d'Entreprises SC SCRL (statutory auditor) and BDO Réviseurs d'Entreprises SC SCRL (statutory auditor)Power of attorney6 facts ▸
Gazette deed
Appointments: KPMG Réviseurs d'Entreprises SC SCRL (statutory auditor) and BDO Réviseurs d'Entreprises SC SCRL (statutory auditor)
Power of attorney6 facts ▸
- General meeting, 15-05-2018
- Auditor appointment, KPMG Réviseurs d'Entreprises SC SCRL (statutory auditor)
- Auditor appointment, BDO Réviseurs d'Entreprises SC SCRL (statutory auditor)
- Power of attorney, Patrick VAN EYCK
- Power of attorney, Régis PANISI
- Power of attorney, Marcos LAMIN BUSSCHOTS
25-06
NBB filing
Annual accounts filed
financial year 2017 · full format
2017
15-12
Gazette deed
Resignations: Frédérique Marie Vogeleisen (personne chargée de la gestion journalière et directeur général) and Bert Vanroye (personne chargée de la gestion journalière et directeur général adjoint)Appointments: Christian Cromlin (personne chargée de la gestion journalière et directeur général) and Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint) · Power of attorney10 facts ▸
Gazette deed
Resignations: Frédérique Marie Vogeleisen (personne chargée de la gestion journalière et directeur général) and Bert Vanroye (personne chargée de la gestion journalière et directeur général adjoint)
Appointments: Christian Cromlin (personne chargée de la gestion journalière et directeur général) and Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint) · Power of attorney10 facts ▸
- Board meeting, 14-11-2017
- Director resignation, Frédérique Marie Vogeleisen (personne chargée de la gestion journalière et directeur général)
- Director resignation, Bert Vanroye (personne chargée de la gestion journalière et directeur général adjoint)
- Power of attorney, El Djouhar Alexandra Rekaï (2 times)
- Power of attorney, Geneviève De Bue (2 times)
- Power of attorney, Mireille Leclercq
- Power of attorney, Serge Doris (2 times)
- Director appointment, Christian Cromlin (personne chargée de la gestion journalière et directeur général)
- Director appointment, Alain Marlier (personne chargée de la gestion journalière et directeur général adjoint)
- Power of attorney, Olivier Gaziaux
13-07
NBB filing
Annual accounts filed
financial year 2016 · full format
03-02
Gazette deed
Amendment of the articles · Name · Resignations & appointmentsName change2 facts ▸
Gazette deed
Amendment of the articles · Name · Resignations & appointments
Name change2 facts ▸
- Name change, PolyPeptide
- Amendment of the articles
24-01
Gazette deed
Resignations: Rodolfo Jose Savitzky, Stefan Heinz Stoffel and Daniel BlättlerAppointments: Jane Salik, Daniel Lasanow and 2 others · Mandate compensation12 facts ▸
Gazette deed
Resignations: Rodolfo Jose Savitzky, Stefan Heinz Stoffel and Daniel Blättler
Appointments: Jane Salik, Daniel Lasanow and 2 others · Mandate compensation12 facts ▸
- Shareholder decision, 03-01-2017
- Director resignation, Rodolfo Jose Savitzky (director)
- Director resignation, Stefan Heinz Stoffel (director)
- Director resignation, Daniel Blättler (director)
- Director appointment, Jane Salik (director)
- Director appointment, Daniel Lasanow (director)
- Director appointment, Jan Fuhr Miller (director)
- Director appointment, Peter Nilsson (director)
- Mandate compensation, Jane Salik
- Mandate compensation, Daniel Lasanow
- Mandate compensation, Jan Fuhr Miller
- Mandate compensation, Peter Nilsson
2016
01-12
Gazette deed
Resignation: Toralf Andrew Haag (director)Appointment: Rodolfo Jose Savitzky (director) · Director discharge · Mandate compensation5 facts ▸
Gazette deed
Resignation: Toralf Andrew Haag (director)
Appointment: Rodolfo Jose Savitzky (director) · Director discharge · Mandate compensation5 facts ▸
- General meeting, 09-11-2016
- Director resignation, Toralf Andrew Haag (director)
- Director discharge, Toralf Andrew Haag (director)
- Director appointment, Rodolfo Jose Savitzky (director)
- Mandate compensation, Rodolfo Jose Savitzky
01-08
Gazette deed
Reappointments: Serge Marie J Doris, Geneviève De Bue and 2 othersAppointments: Frédérique Marie Vogeleiser ep. Mutterer (directeur général) and Bert Irma V Variroye (directeur général adjoint) · Power of attorney14 facts ▸
Gazette deed
Reappointments: Serge Marie J Doris, Geneviève De Bue and 2 others
Appointments: Frédérique Marie Vogeleiser ep. Mutterer (directeur général) and Bert Irma V Variroye (directeur général adjoint) · Power of attorney14 facts ▸
- Board meeting, 01-07-2016
- Power of attorney, Eugénia Tsirimikos
- Director reappointment, Serge Marie J Doris (director)
- Director reappointment, Geneviève De Bue (director)
- Director reappointment, Mireille Colette B. Leclercq (director)
- Director reappointment, El-Djouhar Alexandra Rekai (director)
- Power of attorney, Serge Marie J Doris
- Power of attorney, Geneviève De Bue
- Power of attorney, Mireille Colette B. Leclercq
- Power of attorney, El-Djouhar Alexandra Rekai
- Director appointment, Frédérique Marie Vogeleiser ep. Mutterer (directeur général)
- Director appointment, Bert Irma V Variroye (directeur général adjoint)
- +2 further facts in this act
20-06
Gazette deed
Reappointments: Toralf Haag (director) and Stefan Heinz Stoffel (director)Mandate compensation · Power of attorney8 facts ▸
Gazette deed
Reappointments: Toralf Haag (director) and Stefan Heinz Stoffel (director)
Mandate compensation · Power of attorney8 facts ▸
- General meeting, 17-05-2016
- Director reappointment, Toralf Haag (director)
- Director reappointment, Stefan Heinz Stoffel (director)
- Mandate compensation, Toralf Haag
- Mandate compensation, Stefan Heinz Stoffel
- Power of attorney, Darie Robbrecht
- Power of attorney, Jessica Lanzillotta
- Power of attorney, BVBA Ad-Ministerie
08-02
Gazette deed
MiscellaneousAmendment of the articles1 fact ▸
Gazette deed
Miscellaneous
Amendment of the articles1 fact ▸
- Amendment of the articles
05-01
Gazette deed
Resignations & appointmentsPower of attorney1 fact ▸
Gazette deed
Resignations & appointments
Power of attorney1 fact ▸
- Power of attorney, Ad-Ministerie SPRL
2015
11-12
Gazette deed
Appointment: Klynveld Peat Marwick Goerdeler - KPMG SCRL (statutory auditor)Permanent representative: Alexis Palm · Mandate term4 facts ▸
Gazette deed
Appointment: Klynveld Peat Marwick Goerdeler - KPMG SCRL (statutory auditor)
Permanent representative: Alexis Palm · Mandate term4 facts ▸
- General meeting, 24-11-2015
- Auditor appointment, Klynveld Peat Marwick Goerdeler - KPMG SCRL (statutory auditor)
- Permanent representative, Alexis Palm
- Mandate term, “expire après l'Assemblée Générale des Associés relative aux comptes annuels du 31-12-2017 qui aura lieu en 2018” (deed in French)
2014
03-09
Gazette deed
Resignation: Stephan Kutzer (director)Appointment: Daniel Blättler (director) · Director discharge · Mandate compensation5 facts ▸
Gazette deed
Resignation: Stephan Kutzer (director)
Appointment: Daniel Blättler (director) · Director discharge · Mandate compensation5 facts ▸
- General meeting, 09-07-2014
- Director resignation, Stephan Kutzer (director)
- Director discharge, Stephan Kutzer (director)
- Director appointment, Daniel Blättler (director)
- Mandate compensation, Daniel Blättler
15-04
Gazette deed
Appointment: El Djouhar Alexandra Rekai (daily management delegate)Reappointments: Gerieviève De Bue, Eugénia Tsirimikos and 2 others5 facts ▸
Gazette deed
Appointment: El Djouhar Alexandra Rekai (daily management delegate)
Reappointments: Gerieviève De Bue, Eugénia Tsirimikos and 2 others5 facts ▸
- Director appointment, El Djouhar Alexandra Rekai (daily management delegate)
- Director reappointment, Gerieviève De Bue (mandataire)
- Director reappointment, Eugénia Tsirimikos (mandataire)
- Director reappointment, Mireille Leclercq (mandataire)
- Director reappointment, Serge Doris (mandataire)
19-02
Gazette deed
Resignation: Arjen Vermeer (director)Director discharge3 facts ▸
Gazette deed
Resignation: Arjen Vermeer (director)
Director discharge3 facts ▸
- General meeting, 15-01-2014
- Director resignation, Arjen Vermeer (director)
- Director discharge, Arjen Vermeer (director)
2013
26-07
Gazette deed
Resignations: James Leresche (délégué à la gestion journalière / directeur général) and Laurent Demoisy (mandat)Appointments: Frédérique Vogeleisen (délégué à la gestion journalière / directeur général) and Bert Vanroye (directeur général adjoint) · Power of attorney10 facts ▸
Gazette deed
Resignations: James Leresche (délégué à la gestion journalière / directeur général) and Laurent Demoisy (mandat)
Appointments: Frédérique Vogeleisen (délégué à la gestion journalière / directeur général) and Bert Vanroye (directeur général adjoint) · Power of attorney10 facts ▸
- Board meeting, 30-04-2013
- Director resignation, James Leresche (délégué à la gestion journalière / directeur général)
- Director appointment, Frédérique Vogeleisen (délégué à la gestion journalière / directeur général) (2 times)
- Director appointment, Bert Vanroye (directeur général adjoint)
- Power of attorney, Mireille Leclercq (mandataire spécial)
- Power of attorney, Geneviève De Bue (mandataire spécial)
- Power of attorney, Eugénia Tsirimikos (mandataire spécial)
- Power of attorney, Serge Doris (mandataire spécial)
- Director resignation, James Leresche (mandat)
- Director resignation, Laurent Demoisy (mandat)
28-02
Gazette deed
Permanent representatives: Michel Lange and Alexis PalmAppointments: James Leresche (director) and Bert Vanroye (director)5 facts ▸
Gazette deed
Permanent representatives: Michel Lange and Alexis Palm
Appointments: James Leresche (director) and Bert Vanroye (director)5 facts ▸
- Board meeting, 15-01-2013
- Permanent representative, Michel Lange
- Permanent representative, Alexis Palm
- Director appointment, James Leresche
- Director appointment, Bert Vanroye
24-01
Gazette deed
Capital & shares · Amendment of the articles · Resignations & appointmentsCapital increase · Capital decrease · Capital6 facts ▸
Gazette deed
Capital & shares · Amendment of the articles · Resignations & appointments
Capital increase · Capital decrease · Capital6 facts ▸
- General meeting, 21-12-2012
- Capital increase, €63,800,000
- Capital decrease, €63,800,000
- Capital, €40,000,000
- Amendment of the articles
- Power of attorney, Clifford Chance LLP
2012
06-09
Gazette deed
Resignation: Olivier Ludemann-Hombourger (délégué à la gestion journalière / directeur général adjoint)Appointment: Bert Vanroye (délégué à la gestion journalière / directeur général adjoint) · Power of attorney11 facts ▸
Gazette deed
Resignation: Olivier Ludemann-Hombourger (délégué à la gestion journalière / directeur général adjoint)
Appointment: Bert Vanroye (délégué à la gestion journalière / directeur général adjoint) · Power of attorney11 facts ▸
- Board meeting, 20-07-2012
- Director resignation, Olivier Ludemann-Hombourger (délégué à la gestion journalière / directeur général adjoint)
- Director appointment, Bert Vanroye (délégué à la gestion journalière / directeur général adjoint) (2 times)
- Power of attorney, James Leresche
- Power of attorney, Bert Vanroye
- Power of attorney, Laurent Demoisy
- Power of attorney, Geneviève De Bue
- Power of attorney, Eugenia Tsirimikos
- Power of attorney, Frédérique Mutterer
- Power of attorney, Serge Doris
- Power of attorney, Patrick Loosen
02-07
Gazette deed
Appointment: Klynveld Peat Marwick Goedeler - KPMG SCRL (statutory auditor)Permanent representative: Michel Lange3 facts ▸
Gazette deed
Appointment: Klynveld Peat Marwick Goedeler - KPMG SCRL (statutory auditor)
Permanent representative: Michel Lange3 facts ▸
- General meeting, 15-05-2012
- Auditor appointment, Klynveld Peat Marwick Goedeler - KPMG SCRL (statutory auditor)
- Permanent representative, Michel Lange
28-03
Gazette deed
Resignations & appointmentsPower of attorney5 facts ▸
Gazette deed
Resignations & appointments
Power of attorney5 facts ▸
- Board meeting, 15-02-2012
- Power of attorney, Bert Vanroye
- Power of attorney, Serge Doris
- Power of attorney, Frédérique Mutterer
- Power of attorney, Eugénia Tsirimikos
17-02
Gazette deed
Appointment: Abraham Arjen Vermeer (director)Mandate compensation3 facts ▸
Gazette deed
Appointment: Abraham Arjen Vermeer (director)
Mandate compensation3 facts ▸
- General meeting, 16-01-2012
- Director appointment, Abraham Arjen Vermeer (director)
- Mandate compensation, Abraham Arjen Vermeer
2011
17-06
Gazette deed
Reappointment: Toralf Haag (director)2 facts ▸
Gazette deed
Reappointment: Toralf Haag (director)
2 facts ▸
- General meeting, 17-05-2011
- Director reappointment, Toralf Haag (director)
17-06
Gazette deed
Resignations: Patrick Loosen, Olivier Ludemann-Hombourger and Pascal BrouyèreAppointments: James Leresche, Olivier Ludemann-Hombourger and Patrick Loosen7 facts ▸
Gazette deed
Resignations: Patrick Loosen, Olivier Ludemann-Hombourger and Pascal Brouyère
Appointments: James Leresche, Olivier Ludemann-Hombourger and Patrick Loosen7 facts ▸
- Board meeting, 19-05-2011
- Director resignation, Patrick Loosen (délégué à la gestion journalière et directeur général)
- Director appointment, James Leresche (délégué à la gestion journalière et directeur général)
- Director appointment, Olivier Ludemann-Hombourger (délégué à la gestion journalière et directeur général adjoint)
- Director resignation, Olivier Ludemann-Hombourger (mandataire spécial)
- Director resignation, Pascal Brouyère (mandataire)
- Director appointment, Patrick Loosen (mandataire spécial)
2010
18-11
Gazette deed
Resignations & appointmentsPower of attorney4 facts ▸
Gazette deed
Resignations & appointments
Power of attorney4 facts ▸
- Board meeting, 12-10-2010
- Power of attorney, Olivier Ludemann-Hombourger
- Power of attorney, Stephan Rosenberger
- Power of attorney, Ewald Amherd
22-06
Gazette deed
Resignation: Uwe Boehlke (director)Appointments: Stephan Kutzer (director) and Stefan Stoffel (director)4 facts ▸
Gazette deed
Resignation: Uwe Boehlke (director)
Appointments: Stephan Kutzer (director) and Stefan Stoffel (director)4 facts ▸
- General meeting, 18-05-2010
- Director resignation, Uwe Boehlke (director)
- Director appointment, Stephan Kutzer (director)
- Director appointment, Stefan Stoffel (director)
2009
18-05
Gazette deed
Resignation: Seppe De Gelas (director)Power of attorney8 facts ▸
Gazette deed
Resignation: Seppe De Gelas (director)
Power of attorney8 facts ▸
- Board meeting, 15-04-2009
- Power of attorney, Frédérique Mutterer
- Power of attorney, Seppe De Gelas
- Power of attorney, Pascal Brouyère
- Power of attorney, Eugenia Tsirimikos
- Power of attorney, Ewaid Amherd
- Power of attorney, Serge Doris
- Director resignation, Seppe De Gelas
2008
02-06
Gazette deed
Resignations & appointmentsPower of attorney5 facts ▸
Gazette deed
Resignations & appointments
Power of attorney5 facts ▸
- Board meeting, 30-04-2008
- Power of attorney, James Leresche
- Power of attorney, Ewald Amherd
- Power of attorney, Philippe Simetin
- Power of attorney, Marie-Hélène Brichard
2007
29-08
Gazette deed
Capital & shares · Amendment of the articlesApproval · Capital increase · Capital5 facts ▸
Gazette deed
Capital & shares · Amendment of the articles
Approval · Capital increase · Capital5 facts ▸
- General meeting, 30-07-2007
- Approval, “rapports du conseil d'administration et de KPMG” (deed in French)
- Capital increase, €20,000,000
- Capital, €40,000,000
- Power of attorney, Clifford Chance LLP
18-06
Gazette deed
Resignation: Lukas Utiger (director)Appointment: Uwe Boehlke (director)3 facts ▸
Gazette deed
Resignation: Lukas Utiger (director)
Appointment: Uwe Boehlke (director)3 facts ▸
- General meeting, 15-05-2007
- Director resignation, Lukas Utiger (director)
- Director appointment, Uwe Boehlke (director)
04-06
Gazette deed
Resignations & appointmentsPower of attorney11 facts ▸
Gazette deed
Resignations & appointments
Power of attorney11 facts ▸
- Board meeting, 20-05-2007
- Power of attorney, Patrick Loosen
- Power of attorney, Philippe Simetin
- Power of attorney, Seppe De Gelas
- Power of attorney, Marie-Hélène Brichard
- Power of attorney, Pascal Brouyère
- Power of attorney, Eugenia Tsirimikos
- Power of attorney, Serge Doris
- Power of attorney, Karl-Heinz
- Power of attorney, Raphael Stucky
- Power of attorney, Vincent Bille
2006
26-06
Gazette deed
Resignations & appointmentsPower of attorney · Joint representation10 facts ▸
Gazette deed
Resignations & appointments
Power of attorney · Joint representation10 facts ▸
- Board meeting, 27-04-2009
- Power of attorney, Patrick Loosen
- Power of attorney, Philippe Simetin
- Power of attorney, Seppe De Gelas
- Power of attorney, Karl-Heinz Gratzel
- Power of attorney, Raphael Stucky
- Power of attorney, Marie-Helene Brichard
- Power of attorney, Pascal Brouyere
- Power of attorney, Vincent Bille
- Joint representation, “agissant deux par deux, soit avec un des délégués à la gestion journalière, soit avec un autre mandataire spécial” (deed in French)
13-03
Gazette deed
Appointments: Stéphane Mischler (daily management delegate) and Alain Scarso (daily management delegate)3 facts ▸
Gazette deed
Appointments: Stéphane Mischler (daily management delegate) and Alain Scarso (daily management delegate)
3 facts ▸
- Board meeting, 15-02-2006
- Director appointment, Stéphane Mischler (daily management delegate)
- Director appointment, Alain Scarso (daily management delegate)
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 20 annual accounts filed, the latest 10 are here; all 20 are under Financials.
45 of 45 deeds read
Register details
Identification
Legal formPublic limited company
Founded14-02-2006
Financial year end31-12
Activities, NACEBEL 2025
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
20130Manufacture of chemicals and chemical products
20140Manufacture of chemicals and chemical products
20200Manufacture of chemicals and chemical products
20590Manufacture of chemicals and chemical products
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
Contact
E-mail
PPBE0-HR@polypeptide.comBraine-l'Alleud
Phone
+3223862909Braine-l'Alleud
E-invoicing
Reachable via Peppol
Peppol ID
0208:0879346768
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Recognitions · licences · registrations
Food safety, FASFC
1 siteBraine-l'Alleudunit no. 2.151.696.263
Legal Entity Identifier
894500XRM0N1353TSE52
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
Location & real-estate footprint
Registered office, Braine-l'Alleud · 2 establishment units since 2006
Ground area
8.0 ha
Building footprint
2,404 m²
Building volume
16,476 m³
2 parcels, Flanders, Wallonia · tallest building 11.8 m. Linked by address, not a title deed.
2 establishment units
PolyPeptide
since 2006unit no. 2.151.696.263
Jozef Huysmanslaan 53, 1651 Beersel
since 2024unit no. 2.356.361.810
2 parcels
Flanders
1
(50%)
Wallonia
1
(50%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 25743G0205/00T000 | Wallonia | 7.9 ha | 1 · 1,824 m² | 9.0 m · 3 |
| 23046C0254/02G002 | Flanders | 1,349 m² | 1 · 580 m² | 11.8 m · 2 |
How the parcels are linked
Good to know
Both parcels match the address exactly.
Articles of association
- PurposeThe activities the company may carry out under its articles.
- “La recherche, la fabrication, l'achat, la vente et la transformation de tous ingrédients, matières ou produits chimiques et pharmaceutiques…” (deed in French)deed of 29-12-2021
Text of the purpose (deed in French)
“La recherche, la fabrication, l'achat, la vente et la transformation de tous ingrédients, matières ou produits chimiques et pharmaceutiques, purs, simples ou composés; ainsi que de matières et produits similaires ou connexes. Elle peut également exercer toute activité d'ingénieur conseil, de bureau d'études, de conception ou réalisation d'appareils ou d'entreprises publiques ou privées - y compris l'organisation - rien excepté ni réservé. Elle peut plus généralement entreprendre toutes opérations de commerce, d'industrie et de finance, mobilières, immobilières, agricoles et minières, tant en Belgique qu'à l'étranger, se rattachant, soit directement, soit indirectement, aux dits objets. Elle peut s'intéresser par voie d'apport, de fusion, de souscription ou achat de titres ou droits sociaux, de participation ou de toute autre manière dans toutes entreprises dont l'objet se rattache directement ou indirectement à son industrie ou son commerce. A cet effet, la société peut collaborer et prendre part, ou prendre un intérêt dans d'autres entreprises, directement ou indirectement, de quelque manière que ce soit. La société peut donner caution tant pour ses propres engagements que pour les engagements de tiers, entre autres en donnant ses biens en hypothèque ou en gage, y compris son propre fonds de commerce. La société peut d'une façon générale accomplir toutes opérations commerciales, industrielles, financières, mobilières ou immobilières se rapportant directement ou indirectement à son objet ou qui seraient de nature à en faciliter la réalisation.”
- Who signsWho may bind the company towards others, for example by signing a contract.
- “L'assemblée générale rappelle que, conformément à ses statuts, la Société est valablement représentée comme suit: < La Société est…”deed of 23-03-2023
Read from the deeds: 2 provisions, deed of 23-03-2023